Harnessing Transient Expression Systems with Plant Viral Vectors for the Production of Biopharmaceuticals in Nicotiana benthamiana.

Publication date: Jun 09, 2025

Plant Molecular Farming (PMF) capitalizes on the unique properties of plants as bioreactors to efficiently produce valuable proteins, pharmaceuticals, and enzymes. This review emphasizes the critical role of transient expression systems, particularly in Nicotiana benthamiana, due to its susceptibility to various pathogens. Viral vector-based transient expression has proven essential during health emergencies like COVID-19, enabling rapid recombinant protein production. The review also evaluates different transient expression platforms and highlights their applications in biopharmaceutical production, education, synthetic biology, and gene editing. Advances in viral vector modification, hydroponics, and Controlled Environment Agriculture (CEA) are presented as transformative innovations enhancing scalability and regulatory compliance. Furthermore, glycoengineering advancements broaden the range of producible biopharmaceuticals, improving global medication access. By exploring these advancements, this review underscores the vast potential of transient expression systems to meet dynamic scientific and market demands, positioning PMF as a vital component in modern biotechnology.

Open Access PDF

Concepts Keywords
Biotechnology biopharmaceuticals
Farming Bioreactors
Hydroponics controlled environment agriculture
Valuable COVID-19
Viral Gene Editing
Genetic Vectors
Humans
Molecular Farming
N. benthamiana
Nicotiana
plant molecular farming
Plants, Genetically Modified
Recombinant Proteins
Recombinant Proteins
recombinant proteins
SARS-CoV-2
transient expression

Semantics

Type Source Name
disease IDO production
disease IDO role
disease IDO susceptibility
disease MESH emergencies
disease MESH COVID-19
disease IDO protein
disease MESH medication access
drug DRUGBANK Guanosine
disease MESH arthritis
disease MESH cancer
disease IDO cell
disease IDO process
disease IDO bacteria
disease IDO host
drug DRUGBANK Polyethylene glycol
disease IDO infectivity
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Bean
drug DRUGBANK Spinosad
drug DRUGBANK Taliglucerase alfa
disease MESH Gaucher disease
disease MESH complications
disease IDO quality
pathway KEGG Viral replication
disease IDO infectious agent
disease MESH infection
drug DRUGBANK Aflibercept
disease IDO replication
disease MESH shock
disease MESH death
disease IDO endotoxin
drug DRUGBANK Isoxaflutole
drug DRUGBANK Fenamole
disease MESH viral infections
disease IDO innate immune response
disease IDO country
drug DRUGBANK Coenzyme M
drug DRUGBANK Xylose
drug DRUGBANK Cetuximab
disease MESH malaria
pathway KEGG Malaria
drug DRUGBANK Nicotine
drug DRUGBANK Water
drug DRUGBANK Phencyclidine
pathway REACTOME Translation
disease MESH tic
disease MESH Syndrome
drug DRUGBANK Copper
disease MESH Hepatitis
disease MESH Ebola Virus Disease
disease MESH colon cancer
drug DRUGBANK Atezolizumab
drug DRUGBANK Aprotinin
disease IDO history
disease MESH colorectal carcinoma
drug DRUGBANK PEV3A
disease IDO facility
disease MESH Immobilization

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *